Leon Catherine, Ravanat Catherine, Freund Monique, Cazenave Jean-Pierre, Gachet Christian
Institut National de la Santé et de la Recherche Médicale U.311, Etablissement Français du Sang-Alsace, 10 rue Spielmann, 67065 Strasbourg Cédex, France.
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1941-7. doi: 10.1161/01.ATV.0000092127.16125.E6. Epub 2003 Aug 21.
In vivo, activated platelets contribute to the initiation of thrombin generation through the exposure of phosphatidylserine to form a procoagulant catalytic surface and through platelet-leukocyte interactions, which lead to the exposure of leukocyte tissue factor (TF). On the basis of observations that the platelet P2Y1 and P2Y12 receptors both contribute to thrombosis and thrombin formation in an in vivo model of TF-induced thromboembolism, we further characterized the role of these receptors in thrombin generation.
By using the selective P2 antagonists MRS2179 and AR-C69931MX, the P2Y12 receptor was found to be involved in thrombin-induced exposure of PS on isolated platelets and consequently in TF-induced thrombin formation in platelet-rich plasma. By contrast, the P2Y1 receptor was not involved in phosphatidylserine exposure nor in thrombin generation in platelet-rich plasma. In addition, both receptors were found to contribute to the interactions between platelets and leukocytes mediated by platelet P-selectin exposure, which result in TF exposure at the surface of leukocytes.
Overall, these results point to a differential involvement of the 2 platelet ADP receptors in the generation of thrombin and provide further evidence for the relevance of molecules targeting these receptors as antithrombotic agents.
在体内,活化血小板通过磷脂酰丝氨酸的暴露形成促凝催化表面以及通过血小板 - 白细胞相互作用(导致白细胞组织因子(TF)暴露)来促进凝血酶生成。基于在TF诱导的血栓栓塞体内模型中血小板P2Y1和P2Y12受体均对血栓形成和凝血酶形成有作用的观察结果,我们进一步研究了这些受体在凝血酶生成中的作用。
通过使用选择性P2拮抗剂MRS2179和AR - C69931MX,发现P2Y12受体参与凝血酶诱导的分离血小板上磷脂酰丝氨酸的暴露,进而参与富血小板血浆中TF诱导的凝血酶形成。相比之下,P2Y1受体不参与富血小板血浆中磷脂酰丝氨酸的暴露和凝血酶生成。此外,发现这两种受体均有助于由血小板P - 选择素暴露介导的血小板与白细胞之间的相互作用,这导致白细胞表面TF暴露。
总体而言,这些结果表明两种血小板ADP受体在凝血酶生成中发挥不同作用,并为靶向这些受体的分子作为抗血栓药物的相关性提供了进一步证据。